Axinn Advises Thermo Fisher Scientific in Securing Global Merger-Control Clearances for its Acquisition of Olink Holding
July 10, 2024
Axinn is pleased to represent Thermo Fisher Scientific (NYSE: TMO), a global life sciences leader, in helping obtain unconditional regulatory clearance worldwide in its $3.1 billion acquisition of Olink Holding (Nasdaq: OLK), the Swedish provider of next-generation proteomics solutions.
The team includes partners John Harkrider, Mark Alexander, and Craig Minerva, as well as associates Megan Walden, Heather Zuckert, John Bogert, and Matthew Gorski.
About Axinn
Axinn combines the skills, experience, and dedication of the world’s largest firms with the focus, responsiveness, efficiency, and attention to client needs of the best boutiques. The firm was established in the late 1990s by lawyers from premier Wall Street firms with a common vision: provide the highest level of service and strategic acumen in antitrust, intellectual property, and high-stakes litigation. Axinn’s lawyers have served as lead or co-lead counsel on more than half a trillion dollars in transactions and, in the last 10 years alone, have handled more than 500 litigations.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
ABA 73rd Annual Section of Antitrust Law Spring Meeting
Speaking Engagement
Antitrust
AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice
Speaking Engagement
17th Annual Practitioners' Think Tank on ITC Litigation & Enforcement
Speaking Engagement
Intellectual Property
Antitrust Enforcement Trends and Policies in 2025: Unfair Competition, Merger Policies, Premerger Procedures
Webinar
Antitrust
CompLaw Nordic 2025
Speaking Engagement
Antitrust
Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Axinn Viewpoints
Intellectual Property